OncoSec Medical Inc (NASDAQ:ONCS) CEO Daniel J. O’connor bought 16,667 shares of OncoSec Medical stock in a transaction that occurred on Monday, February 5th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $25,000.50. Following the acquisition, the chief executive officer now directly owns 16,667 shares in the company, valued at approximately $25,000.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of OncoSec Medical Inc (ONCS) traded down $0.09 during mid-day trading on Tuesday, reaching $1.67. 367,613 shares of the company’s stock were exchanged, compared to its average volume of 1,026,644. OncoSec Medical Inc has a 52-week low of $0.88 and a 52-week high of $2.95. The firm has a market cap of $61.80, a price-to-earnings ratio of -1.69 and a beta of 3.37.
Several research firms recently weighed in on ONCS. HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the company a “buy” rating in a report on Friday, January 19th. Maxim Group set a $5.00 target price on shares of OncoSec Medical and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. OncoSec Medical presently has an average rating of “Buy” and a consensus target price of $5.33.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.